Keymed Biosciences Inc. announced that as of February 28, 2026, authorized share capital remained at 500.00 million shares, each with a par value of USD 0.0001, totaling USD 0.05 million in authorized capital. The issued share count was 298.74 million shares, unchanged from the previous month.

No share options, warrants, convertibles, or other arrangements were disclosed. The company confirmed compliance with the minimum public float requirement, which stands at 25% of the issued shares (excluding any treasury shares). The information was submitted on March 2, 2026, by the company’s executive director.